Veenat 400mg Tablets Veenat 400 contains Imatinib Mesylate, a protein-tyrosine kinase inhibitor that selectively inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It also inhibits receptor tyrosine kinases for platelet-derived growth factor (PDGFR) and stem cell factor (SCF) / c-KIT. By binding competitively to the ATP-binding site of these tyrosine kinases, Imatinib prevents substrate phosphorylation, blocking cell proliferation and signaling cascades to induce apoptosis in BCR-ABL-positive cells and c-KIT-expressing tumor cells. Veenat® 400 is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), gastrointestinal stromal tumors (GIST), and myelodysplastic/myeloproliferative diseases.